2-氨基-1-(4-氟苯基)-1-丙酮盐酸盐 | 322-30-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-氨基-1-(4-氟苯基)-1-丙酮盐酸盐
• 英文名称: 2-amino-1-(4-fluorophenyl)-1-propanone hydrochloride
• 英文别名: norflephedrone hydrochloride；2-amino-1-(4-fluoro-phenyl)-propan-1-one; hydrochloride；2-Amino-1-(4-fluor-phenyl)-propan-1-on; Hydrochlorid；2-amino-1-(4-fluorophenyl)propan-1-one;hydrochloride
• CAS: 322-30-5
• 化学式: C₉H₁₀FNO*ClH
• 分子量: 203.644
• InChiKey: YIFQWFTZZSOAEG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.78
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  43.1
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-氨基-1-(4-氟苯基)-1-丙酮盐酸盐 在 sodium tetrahydroborate 、 四丙基高钌酸铵 、 4 A molecular sieve 、 二乙基甲氧基硼烷 、 氢氟酸 、 sodium acetate 、 sodium hydride 、 二异丁基氢化铝 、 溶剂黄146 、 N-甲基吗啉氧化物 作用下， 以 二氯甲烷 、 水 、 甲苯 、 乙腈 为溶剂， 反应 28.5h， 生成 (3R,5S)-7-[4-(4-fluorophenyl)-2-isopropyl-1-(methanesulfonyl)-5-methyl-1H-pyrrol-3-yl]-3,5-dihydroxy-6-heptenoic acid methyl ester
  参考文献：
  名称：

  Synthesis and Biological Activity of Methanesulfonamide Pyrimidine- and N-Methanesulfonyl Pyrrole-Substituted 3,5-Dihydroxy-6-heptenoates, a Novel Series of HMG-CoA Reductase Inhibitors

  摘要：

  A novel series of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates were synthesized and evaluated for their ability to inhibit the enzyme HMG-CoA reductase in vitro. Monocalcium bis(+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methanesulfonylaminopyrimidin)-5-yl]-(3R,5S)-dihydroxy-(E)-6-heptenoate (3a,S-4522) was selected as a candidate for further evaluation. Compound 3a was approximately four times more potent than lovastatin sodium salt (in inhibiting HMG-CoA reductase in vitro (IC50 = 11 nM). Compound 3a was shown to be the most potent cholesterol biosynthesis inhibitor in this series (IC50 = 1.12 nM) in rat isolated hepatocytes; its inhibitory activity was approximately 100 times more potent than pravastatin. (C) 1997, Elsevier Science Ltd.

  DOI：

  10.1016/s0968-0896(96)00248-9
• 作为产物：
  描述：

  4'-氟苯丙酮 在 盐酸 、 sodium azide 、 溴 、 亚磷酸三乙酯 作用下， 以 四氯化碳 、 甲苯 、 乙腈 为溶剂， 反应 5.0h， 生成 2-氨基-1-(4-氟苯基)-1-丙酮盐酸盐
  参考文献：
  名称：

  N.C.A.18F-labelled norephedrine derivatives via α-aminopropiophenones

  摘要：

  N-protected 2-anlino-1-([F-18]fluorophenyl)-1-propanones are interesting fluorine-18 labelled intermediates to synthesize potential PET-tracers for mapping the adrenergic nervous system of the heart. Several N-protected alpha -aminoalkylarylketones were prepared to examine the direct nucleophilic n.c.a. F-18-fluorination of these carbonyl activated precursors. The influence of different protecting groups, the kind of leaving group and the stereoselective reduction of the keto function have been investigated in order to optimize the radiotracer production. It was shown that the F-18-substitution of the para-trimethylammonium group, e.g. of N-dibenzylated propiophenone, leads to radiochemical yields of up to 60%. The stereoselective reduction of the carbonyl function with formation of the n.c.a. erythro 2-N,N-dibenzylamino-1-(4-[F-18]fluorophenyl)-1-propanol was performed using BH3. THF. The diastereomeric excess was about 80%. Hydrogenolytical debenzylation was achieved with ammonium formiate in presence of palladium on charcoal to give the 4-[F-18]fluoronorephedrine with a radiochemical yield of 15-20% within a total time of 60 min.

  DOI：

  10.1002/1099-1344(200012)43:14<1345::aid-jlcr424>3.0.co;2-n

文献信息

• [EN] METALLOENZYME INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DE MÉTALLOENZYMES
  申请人：VPS 3 INC

  公开号：WO2018165520A1

  公开（公告）日：2018-09-13

  Provided are compounds having HDAC6 modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by HDAC6.

  提供具有HDAC6调节活性的化合物，以及通过HDAC6介导的治疗疾病、疾病或症状的方法。
• Structural spectroscopic study of enantiomerically pure synthetic cathinones and their major metabolites
  作者：Dita Spálovská、Martin Paškan、Bronislav Jurásek、Martin Kuchař、Michal Kohout、Vladimír Setnička

  DOI：10.1039/d0nj05065b

  日期：——

  structure is crucial. Here, we present a comprehensive spectroscopic structural study of synthetic cathinones (clephedrone, flephedrone, and brephedrone) and their major human metabolites, desmethyl derivatives. Chiral high-performance liquid chromatography was utilized to obtain the individual enantiomers of the parent synthetic cathinones and their assumed major metabolites synthesized de novo. The

  新的精神活性物质（NPS）已成为非法滥用药物的流行替代品。但是，要确定它们在人体中的代谢途径，对其结构的详细了解至关重要。在这里，我们对合成的卡西酮（麻黄酮，麻黄酮和麻黄酮）及其主要的人体代谢产物去甲基衍生物进行了全面的光谱结构研究。手性高效液相色谱用于获得母体合成卡西酮的单个对映异构体及其从头合成的主要代谢产物。所开发的色谱方法使得有可能以毫克级获得目标光学纯物质。电子和振动圆二色性，结合红外和紫外光谱并得到DFT计算的支持，以确定它们的绝对构型和手法，以详细阐明其分子结构。在水溶液中发现每种物质的两个稳定构象异构体。根据玻尔兹曼分布估计它们的相对丰度，并获得种群加权光谱。实验光谱和模拟光谱之间实现了非常好的一致性，从而可以在水溶液中确定所研究物质的3D结构。
• Electrochemical Desulfurative Cyclization Accessing Oxazol-2-amine Derivatives via Intermolecular C–N/C–O Bond Formation
  作者：Jinhui Hu、Huanliang Hong、Yongwei Qin、Yunfei Hu、Suyun Pu、Gen Liang、Yubing Huang

  DOI：10.1021/acs.orglett.0c04218

  日期：2021.2.5

  diverse oxazol-2-amine derivatives in one step via the electrochemical desulfurative cyclization of isothiocyanates and α-amino ketones. On the basis of the cycle of in situ generation of iodine/desulfurative cyclization/iodide anion regeneration, the reaction is performed under metal-free and external-oxidant-free electrolytic conditions to achieve the formation of intermolecular C–O and C–N bonds, providing

  已经建立了一种实用的协议，可通过异硫氰酸酯和α-氨基酮的电化学脱硫环化一步来获得各种恶唑-2-胺衍生物。根据原位生成碘/脱硫环化/碘阴离子再生的循环，该反应在无金属和无外部氧化剂的电解条件下进行，以形成分子间的C-O和C-N键，以中等至极高的收率提供恶唑-2-胺。
• Pyrrole derivatives
  申请人：SHIONOGI SEIYAKU KABUSHIKI KAISHA

  公开号：EP0464845A1

  公开（公告）日：1992-01-08

  The compounds of the present invention inhibit the HMG-CoA reductase, and subsequently suppress the synthesis of cholesterol. And they are useful in the treatment of hypercholesterolemia, hyperlipoproteinemia, and atherosclerosis.

  本发明的化合物可抑制 HMG-CoA 还原酶，从而抑制胆固醇的合成。 它们可用于治疗高胆固醇血症、高脂蛋白血症和动脉粥样硬化。
• Metalloenzyme inhibitor compounds
  申请人：Selenity Therapeutics (Bermuda), Ltd.

  公开号：US10357493B2

  公开（公告）日：2019-07-23

  Provided are compounds having HDAC6 modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by HDAC6.

  本文提供了具有 HDAC6 调节活性的化合物，以及治疗由 HDAC6 介导的疾病、失调或症状的方法。